SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation

Fieke W. Hoff; Suleyman Y. Goksu; Naveen Premnath; Prapti A. Patel; Ruth Ikpefan; Gurbakhash Kaur; Madhuri Vusirikala; Taha Bat; Weina Chen; Praveen Ramakrishnan Geethakumari; Larry D. Anderson; Farrukh T. Awan; Robert H. Collins; Olga K. Weinberg; Alagarraju Muthukumar; Stephen S. Chung; Yazan F. Madanat

doi:10.5644/ama2006-124.399

SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation

Fieke W. Hoff, Suleyman Y. Goksu, Naveen Premnath, Prapti A. Patel, Ruth Ikpefan, Gurbakhash Kaur, Madhuri Vusirikala, Taha Bat, Weina Chen, Praveen Ramakrishnan Geethakumari, Larry D. Anderson, Farrukh T. Awan, Robert H. Collins, Olga K. Weinberg, Alagarraju Muthukumar, Stephen S. Chung, Yazan F. Madanat

Research output: Contribution to journal › Article › peer-review

Abstract

Objective. Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malig-nancies. Methods. Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer. Results. Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine. Conclusion. Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.

Original language	English (US)
Pages (from-to)	30-36
Number of pages	7
Journal	Acta medica academica
Volume	52
Issue number	1
DOIs	https://doi.org/10.5644/ama2006-124.399
State	Published - 2023

Keywords

Antibody Response
Hematologic Malignancy
SARS-CoV-2 Vaccination

ASJC Scopus subject areas

General Medicine

Access to Document

10.5644/ama2006-124.399

Cite this

Hoff, F. W., Goksu, S. Y., Premnath, N., Patel, P. A., Ikpefan, R., Kaur, G., Vusirikala, M., Bat, T., Chen, W., Geethakumari, P. R., Anderson, L. D., Awan, F. T., Collins, R. H., Weinberg, O. K., Muthukumar, A., Chung, S. S., & Madanat, Y. F. (2023). SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation. Acta medica academica, 52(1), 30-36. https://doi.org/10.5644/ama2006-124.399

Hoff, FW, Goksu, SY, Premnath, N, Patel, PA, Ikpefan, R, Kaur, G, Vusirikala, M, Bat, T , Chen, W , Geethakumari, PR , Anderson, LD , Awan, FT , Collins, RH , Weinberg, OK , Muthukumar, A , Chung, SS & Madanat, YF 2023, 'SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation', Acta medica academica, vol. 52, no. 1, pp. 30-36. https://doi.org/10.5644/ama2006-124.399

@article{5c0f17fb43bb4dcab0a7cca2afb7812b,

title = "SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation",

abstract = "Objective. Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malig-nancies. Methods. Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer. Results. Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine. Conclusion. Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.",

keywords = "Antibody Response, Hematologic Malignancy, SARS-CoV-2 Vaccination",

author = "Hoff, {Fieke W.} and Goksu, {Suleyman Y.} and Naveen Premnath and Patel, {Prapti A.} and Ruth Ikpefan and Gurbakhash Kaur and Madhuri Vusirikala and Taha Bat and Weina Chen and Geethakumari, {Praveen Ramakrishnan} and Anderson, {Larry D.} and Awan, {Farrukh T.} and Collins, {Robert H.} and Weinberg, {Olga K.} and Alagarraju Muthukumar and Chung, {Stephen S.} and Madanat, {Yazan F.}",

note = "Publisher Copyright: {\textcopyright} 2023 Hoff et al.",

year = "2023",

doi = "10.5644/ama2006-124.399",

language = "English (US)",

volume = "52",

pages = "30--36",

journal = "Acta medica academica",

issn = "1840-1848",

publisher = "Academy of Sciences and Arts of Bosnia and Herzegovina",

number = "1",

}

TY - JOUR

T1 - SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort

T2 - A Single Center Observation

AU - Hoff, Fieke W.

AU - Goksu, Suleyman Y.

AU - Premnath, Naveen

AU - Patel, Prapti A.

AU - Ikpefan, Ruth

AU - Kaur, Gurbakhash

AU - Vusirikala, Madhuri

AU - Bat, Taha

AU - Chen, Weina

AU - Geethakumari, Praveen Ramakrishnan

AU - Anderson, Larry D.

AU - Awan, Farrukh T.

AU - Collins, Robert H.

AU - Weinberg, Olga K.

AU - Muthukumar, Alagarraju

AU - Chung, Stephen S.

AU - Madanat, Yazan F.

PY - 2023

Y1 - 2023

N2 - Objective. Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malig-nancies. Methods. Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer. Results. Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine. Conclusion. Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.

AB - Objective. Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malig-nancies. Methods. Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer. Results. Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine. Conclusion. Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.

KW - Antibody Response

KW - Hematologic Malignancy

KW - SARS-CoV-2 Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85163145028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85163145028&partnerID=8YFLogxK

U2 - 10.5644/ama2006-124.399

DO - 10.5644/ama2006-124.399

M3 - Article

C2 - 37326395

AN - SCOPUS:85163145028

SN - 1840-1848

VL - 52

SP - 30

EP - 36

JO - Acta medica academica

JF - Acta medica academica

IS - 1

ER -

SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this